In 466 adults with untreated advanced NSCLC without EGFR, ALK or ROS1 aberrations, 5-year follow-up showed cemiplimab plus chemotherapy improved median OS vs chemotherapy alone (21.1 vs 12.9 months; HR 0.66); grade ≥3 adverse events 49.4% vs 32.7%.
RCTn = 466
Baramidze et al. Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-Year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial